GKOS

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Glaukos Corporation

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
CEO
Thomas Burns
Employees
653
Headquarters

229 Avenida Fabricante
San Clemente, California 92672-7531
Phone: 19493679600
www.glaukos.com

News

Glaukos Corporation PT Raised to $54 at Citi
Aug 04, 2022 11:10am

https://www.investing.com/news/pro/glaukos-corporation-pt-raised-to-54-at-citi-432SI-2863376


Source:Investing.com
Glaukos Corporation (GKOS) CEO Tom Burns on Q2 2022 Results Earnings Call Transcript
Aug 04, 2022 01:36am

Glaukos Corporation (NYSE:NYSE:GKOS) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and…


Source:Seeking Alpha
Recap Of Wednesday''s Biotech Catalysts - End Of the Day Summary
Aug 03, 2022 22:24pm

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound ’s (NASDAQ: MDWD ) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day volume of 283.18 thousand shares, closed regular trading session at $1.67. The company shares are currently trading at $1.77, up 5.99 percent in the after-hours trading session. Alnylam (NASDAQ: ALNY ) announced positive results from the APOLLO-B Phase 3 study of Patisiran for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Alnylam shares traded in a range of $198 to $220.92 on a day volume of 8.54 million shares, closed regular trading session at $212.01. The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Glaukos ’ (NYSE: GKOS ) iStent infinite Trabecular Micro-Bypass System indicated for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma uncontrolled by prior medical and surgical therapy.


Source:Benzinga
Glaukos: Q2 Earnings Insights
Aug 03, 2022 22:12pm

Glaukos (NYSE: GKOS ) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Glaukos missed estimated earnings by 88.64%, reporting an EPS of $-0.83 versus an … Full story available on Benzinga.com


Source:Benzinga
Glaukos Non-GAAP EPS of -$0.83 misses by $0.39, revenue of $72.69M beats by $4.7M (NYSE:GKOS)
Aug 03, 2022 20:51pm

Glaukos press release (GKOS): Q2 Non-GAAP EPS of -$0.83 misses by $0.39.Revenue of $72.69M (-6.9% Y/Y) beats by $4.7M.The company expects 2022 net sales to be in the range of…


Source:Seeking Alpha
The 6 Most Aggressive Growth Stocks to Buy in July
Jul 12, 2022 15:27pm

Today I am discussing the six most aggressive growth stocks to buy in July. They reflect huge potential growth in their sales and/or their earnings. That means their valuations may be quite high, reflecting optimism about that growth. Aggressive growth stocks tend to get bid up due to the market’s enthusiasm over the company’s future prospects. Typically, this relates primarily to sales growth trajectories. As a result, many of these stocks have high price-to-sales multiples. Moreover, in many cases, the high-growth stock does not have positive earnings yet. Or it may have very low adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) figures. As a result, the price-to-adjusted EBITDA, or enterprise value (EV)-to-adjusted EBITDA multiples typically are high. EBITDA is sort of a “poor man’s earnings.” It cuts corners to try to show that the company has positive income. But that company’s actual net income, and even its cash flow, are often negative. For example, by cutting out the real cash costs of interest and taxes, which most companies have to pay, EBITDA shows profitability.


Source:InvestorPlace
Benzinga''s Top Ratings Upgrades, Downgrades For July 12, 2022
Jul 12, 2022 14:21pm

Upgrades For Herbalife Nutrition Ltd (NYSE: HLF ), Jefferies upgraded the previous rating of Hold to Buy. For the first quarter, Herbalife Nutrition had an EPS of $0.99, compared to year-ago quarter EPS of $1.42. The stock has a 52-week-high of $54.45 and a 52-week-low of $19.30. At the end of the last trading period, Herbalife Nutrition closed at $19.71. According to Susquehanna, the prior rating for Southwest Airlines Co (NYSE: LUV ) was changed from Neutral to Positive. For the first quarter, Southwest Airlines had an EPS of $0.32, compared to year-ago quarter EPS of $1.72. At the moment, the stock has a 52-week-high of $56.33 and a 52-week-low of $34.36. Southwest Airlines closed at $36.83 at the end of the last trading period. For Ryan Specialty Holdings Inc (NYSE: RYAN ), Goldman Sachs upgraded the previous rating of Neutral to Buy. The current stock performance of Ryan Specialty Holdings shows a 52-week-high of $42.43 and a 52-week-low of $25.57. Moreover, at the end of the last trading period, the closing price was at $39.70.


Source:Benzinga
Glaukos gains as Stifel upgrades to Buy citing 2022 sales upside
Jul 12, 2022 14:12pm

Glaukos Corporation (GKOS) a health equipment maker focused on eye diseases such as Glaucoma, is trading higher in the morning hours Tuesday after Stifel upgraded its shares to Buy…


Source:Seeking Alpha
US Solar launches community solar program with $100,000 donation to Colorado organizations
Jun 21, 2022 00:00am

US Solar announced the groundbreaking of USS Giveback, its first community solar gardens with Black Hills Energy in Pueblo, Colorado. The 2-MW and 500-kW community solar arrays will serve businesses, residents, municipalities and low- to moderate-income service organizations in the greater Colorado area. As part of its commitment to Black Hills Energy and the community,…


Source:WTWH